ArticleAnimal models and experimental medicine2026
Development of an in situ small intestinal injection technique for targeted macromolecule delivery and in vivo functional studies in mice.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of an in situ small intestinal injection technique for targeted macromolecule delivery and in vivo functional studies in mice.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTargeted delivery of biological macromolecules to the small intestine remains challenging due to their susceptibility to degradation in the hostile gastric environment.
methodsThis study introduces a minimally invasive, in situ injection technique for the murine small intestine that facilitates localized luminal delivery while circumventing gastric barriers. The procedure involves a small abdominal incision for direct injection into the duodenum near the pylorus. Postsurgical monitoring of physiological parameters, systemic inflammatory markers, liver function, and intestinal integrity was conducted over 72 h. Histopathological analysis was performed. The delivery of the functional protein TAT-EGFP (Tat protein fused to enhanced green fluorescent protein) to intestinal epithelial cells was evaluated and compared with oral gavage. As a proof of concept, single-cell RNA sequencing of the intestinal epithelium was performed after high-mobility group box 1 administration.
resultsPostsurgical monitoring indicated only transient, anesthesia-related hypothermia and minor behavioral alterations. No significant changes were observed over 72 h in body weight, core temperature, clinical severity scores, systemic inflammatory markers (C-reactive protein and leukocytes), liver function (alanine aminotransferase), or intestinal integrity. Histopathological analysis confirmed preserved tissue architecture and normal digestive, absorptive, and barrier functions. The model successfully delivered TAT-EGFP to intestinal epithelial cells, an outcome not achievable via oral gavage due to gastric degradation. Single-cell RNA sequencing of the intestinal epithelium after high-mobility group box 1 administration revealed inflammatory gene expression patterns in specific epithelial subpopulations.
conclusionsCompared to traditional methods such as oral gavage or organoid culture, this technique offers precise, degradation-resistant delivery of macromolecules in a physiological context. The model's versatility makes it a powerful platform for intestinal research, with applications in drug delivery assessment, gene therapy evaluation, and host-microbiota interaction studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.